The company stated in its november newsletter it expects to see strong returns and high growth in the coming quarters and they have set ambitious targets they expect to meet and exceed. Now we will have to wait to see the results.
Key findings at the recent European Burns Congress were :
Recell found to be a safe and easy technique providing a viable and valuable method for partial thickness injuries.
Extremely good results for facial wounds with significantly improved cosmetic outcomes.
The large majority of wounds were fully epithelialized in 7-14days (vs 21-40 days for standard skin grafts).
Recell provided significant benefits and advantages over standard techniques including :
Decreased donor site size and minimized morbidity
No post operative pain at the donor site
No rejection of applied cells at donor or wound site
Requirement of only a single operation to harvest and to cover the wound area with cell suspension
Rapid healing with excellent cosmetic outcomes
AVH Price at posting:
16.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)